Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Richard Hickey"'
Autor:
Jingjing Zhang, Luong T. H. Nguyen, Richard Hickey, Nicole Walters, Xinyu Wang, Kwang Joo Kwak, L. James Lee, Andre F. Palmer, Eduardo Reátegui
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
Abstract Extracellular vesicles (EVs) derived from tumor cells have the potential to provide a much-needed source of non-invasive molecular biomarkers for liquid biopsies. However, current methods for EV isolation have limited specificity towards tum
Externí odkaz:
https://doaj.org/article/1da76a5ccfd04a989da3fc36409bd677
Publikováno v:
PLoS ONE, Vol 17, Iss 2, p e0263782 (2022)
Methemoglobin (metHb) arises from the oxidation of ferrous hemoglobin (HbFe2+, Hb) to ferric hemoglobin (HbFe3+, metHb), which is unable to bind gaseous ligands such as oxygen (O2) and carbon monoxide (CO), and binds to nitric oxide (NO) significantl
Externí odkaz:
https://doaj.org/article/477676030ef64c189564ca17ed711967
Publikováno v:
Entrepreneurship and Sustainability Issues, Vol 4, Iss 3, Pp 380-391 (2017)
Externí odkaz:
https://doaj.org/article/c3c2ddcdb1d44a01bd93297cef64ea06
Autor:
Clayton T. Cuddington, Savannah R. Wolfe, Donald A. Belcher, Megan Allyn, Alisyn Greenfield, Xiangming Gu, Richard Hickey, Shuwei Lu, Tanmay Salvi, Andre F. Palmer
Publikováno v:
Biotechnology and bioengineeringREFERENCES. 119(12)
Polymerized human hemoglobin (PolyhHb) is being studied as a possible red blood cell (RBC) substitute for use in scenarios where blood is not available. While the oxygen (Osub2/sub) carrying capacity of PolyhHb makes it appealing as an Osub2/subthera
Publikováno v:
ACS Applied Nano Materials. 3:11736-11742
Engineered hemoglobin (Hb) particles are O2 delivery vehicles that may be used as red blood cell (RBC) substitutes when blood is unavailable. One promising method produces high-purity Hb particles ...
Autor:
Clayton Cuddington, Savannah R. Wolfe, Donald A. Belcher, Megan Allyn, Alisyn Greenfield, Xiangming Gu, Richard Hickey, Shuwei Lu, Andre Palmer
Polymerized human hemoglobin (PolyhHb) is being studied as a possible red blood cell (RBC) substitute for use in scenarios where blood is not available. While the O carrying capacity of PolyhHb makes it appealing as an O therapeutic, the commercial P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48f437e748381f7017d1f9d95e60db76
https://doi.org/10.22541/au.164600516.65619478/v1
https://doi.org/10.22541/au.164600516.65619478/v1
Autor:
Christopher J Gilbert, Maria Belicak, Andre F. Palmer, Chintan Savla, Pedro Cabrales, Carlos Munoz, Richard Hickey
Publikováno v:
ACS biomaterials science & engineering, vol 6, iss 9
Oxygen therapeutics are being developed for a variety of applications in transfusion medicine. In order to reduce the side-effects (vasoconstriction, systemic hypertension, and oxidative tissue injury) associated with previous generations of oxygen t
Autor:
Donald A. Belcher, Colbert F. Miller, Abraham K. Badu-Tawiah, Paul W. Buehler, Andre F. Palmer, Jin Hyen Baek, Ivan S. Pires, Richard Hickey
Publikováno v:
Biotechnology and Bioengineering. 117:125-145
Apohemoglobin (apoHb) is a dimeric globular protein with two vacant heme-binding pockets that can bind heme or other hydrophobic ligands. Purification of apoHb is based on partial hemoglobin (Hb) unfolding to facilitate heme extraction into an organi
Autor:
Richard E. Showalter, Jim Thomson, Yudou He, Mario Meng-Chiang Kuo, Richard Hickey, Wei-Jong Shia, Li-Chang Chen, Elena Brin, Eleanor Dagostino, Katherine Wu, Robert Almassy, Mariusz Stempniak
Publikováno v:
Oncotarget
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) binds to death receptors and induces apoptosis in various cancer cell lines while sparing normal cells. Recombinant TRAIL has shown good safety and efficacy profiles in preclinical
Autor:
Chintan, Savla, Carlos, Munoz, Richard, Hickey, Maria, Belicak, Christopher, Gilbert, Pedro, Cabrales, Andre F, Palmer
Publikováno v:
ACS Biomater Sci Eng
Oxygen therapeutics are being developed for a variety of applications in transfusion medicine. In order to reduce the side-effects (vasoconstriction, systemic hypertension, and oxidative tissue injury) associated with previous generations of oxygen t